Bioanalysis of the Bicycle ® toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry.
Joseph A TweedFern Adams-DamJane AllansonKevin HolmesRyan SeniorHongmei XuMengyao LiGavin BennettPhil JeffreyPublished in: Bioanalysis (2023)
Background: The Bicycle ® toxin conjugate BT5528 is a novel peptide therapeutic conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). A bioanalytical assay was developed to quantify BT5528 and unconjugated MMAE in human plasma. Methodology: BT5528 quantitation used a protein precipitation procedure followed by LC-MS/MS detection. Quantitation of MMAE required a selective offline and online solid-phase extraction with detection via LC-MS/MS. Results: BT5528 was quantified over the assay range of 5-2500 ng/ml and free MMAE was quantified over the assay range of 0.05-50 ng/ml. Conclusion: Bioanalytical methods were used in the bioanalysis of intact BT5528 and released MMAE, in a phase I/IIa clinical trial; to date, over 2000 human patient samples have been analyzed.
Keyphrases
- liquid chromatography tandem mass spectrometry
- solid phase extraction
- simultaneous determination
- ms ms
- high performance liquid chromatography
- high throughput
- clinical trial
- escherichia coli
- molecularly imprinted
- tandem mass spectrometry
- liquid chromatography
- gas chromatography mass spectrometry
- endothelial cells
- gas chromatography
- label free
- photodynamic therapy
- randomized controlled trial
- cancer therapy
- minimally invasive
- health information
- open label
- double blind
- small molecule
- high resolution